Welcome to ASX Exopharm., page-57

It’s great to see unbiased unpumping decent factual scientific based discussions here. I saw this M&A news

https://cen.acs.org/business/mergers-&-acquisitions/Bio-Techne-acquires-Exosome-Diagnostics/96/i27

and realized how darn cheap we are with EX1 with its unique LEAP and founder Dixon when they paid over USD $600 mil for the acquisition of an Exome firm. No wonder EX1 is having fuc* all sell side as investors realizing its massive potential where if things go well with LEAP and human trials starting in 3 months we could be looking at few dollars a share. Of course for that to happen trials need to be successful and Dixon is full of condense on that front. This might do A3D at its best ($5 on the top but EX1 has the potential to out do that easily with LEAP and successful trials) look like a juvenile when EX1 is in full swing. I predicted 2 trading days ago this will close at a new high since listing. It took 1 day to do that even to my surprise. Let’s see where it goes by the end of this trading week! I am gob smacked at EX1’s potential after lots of research over the XMas break. No wonder it did this well in this brutal market.